home / lobbying

lobbying_activities

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

1,668 rows where filing_year = 2025 and issue_code = "PHA" sorted by filing_year descending

✎ View and edit SQL

This data as json, CSV (advanced)

Suggested facets: received_date (date)

filing_period 4

  • first_quarter 552
  • second_quarter 440
  • third_quarter 344
  • fourth_quarter 332

issue_code 1

  • PHA · 1,668 ✖

filing_year 1

  • 2025 · 1,668 ✖
id filing_uuid filing_type registrant_name registrant_id client_name filing_year ▲ filing_period issue_code specific_issues government_entities income_amount expense_amount is_no_activity is_termination received_date
3327470 CARD & ASSOCIATES, LLC 61760c0d-5de8-43b5-bc49-a7feb75b0349 1T CARD & ASSOCIATES, LLC 84217 AMAZON.COM (FRA PILLPACK AN AMAZON COMPANY) 2025 first_quarter PHA Monitor legislation on drug price transparency and market access issues including legislative proposals related to drug pricing Monitor FY 2025 Appropriations Support access to telehealth Monitor and engage on EU & Canadian digital regulatory policies Monitor international trade issues HOUSE OF REPRESENTATIVES,SENATE 50000   0 1 2025-02-14T08:25:55-05:00
3327745 CHRISTIANACARE 32450824-5cf9-4d39-9638-055fb9abe470 Q1 CHRISTIANACARE 401105790 CHRISTIANACARE 2025 first_quarter PHA Issues related to the 340B Drug Pricing Program. HOUSE OF REPRESENTATIVES,SENATE   8000 0 0 2025-03-26T12:49:16-04:00
3328295 BUCHANAN INGERSOLL & ROONEY PC 769fe845-fb48-40aa-aa98-725448408b14 Q1 BUCHANAN INGERSOLL & ROONEY PC 55291 AIM IMMUNOTECH INC. 2025 first_quarter PHA Strategy development and implementation of company's federal government relations initiatives relating to research and development of therapeutics. Work with Department of Defense on Ebola countermeasures. Comprehensive Access to Resources and Education (CARE) For Long COVID Act Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2025-04-02T11:32:24-04:00
3328535 AMERICAN COLLEGE OF CLINICAL PHARMACY 321b12aa-1d40-42ac-b650-110903870be3 Q1 AMERICAN COLLEGE OF CLINICAL PHARMACY 57258 AMERICAN COLLEGE OF CLINICAL PHARMACY 2025 first_quarter PHA Coverage for direct patient care services of qualified pharmacists under Medicare and other public health programs. HOUSE OF REPRESENTATIVES,SENATE   144981 0 0 2025-04-03T09:13:16-04:00
3328877 AEGIS LLC 09f594e6-84e2-4a80-9272-e6905d783c15 Q1 AEGIS LLC 401108688 PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA 2025 first_quarter PHA Pharmacy Benefit Manager (PBM) issues and reform. 340B. IRA implementation. H.R.1492: Ensuring Pathways to Innovative Cures (EPIC) Act. Drug pricing. International reference pricing. H.R.5378 - Lower Costs, More Transparency Act. H.R.5376 - Share the Savings with Seniors Act. H.R.6283/S.1542 - DRUG Act. H.R.830 - HELP Copays Act. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2025-04-04T14:22:12-04:00
3328879 AEGIS LLC d4962b4f-e763-492e-a131-8292f7e96b6c Q1 AEGIS LLC 401108688 TRIS PHARMA, INC. 2025 first_quarter PHA ADHD treatment. Implementation of the Infrastructure Investment and Jobs Act (or bipartisan infrastructure law). Traffic safety (distracted and impaired driving). Issues related to FDA approval. Patient access to non-opioid pain medicines. NO PAIN Act implementation. H.R.1227 / S.475: Alternatives to PAIN Act. HOUSE OF REPRESENTATIVES,Natl Highway Traffic Safety Administration (NHTSA),SENATE 50000   0 0 2025-04-04T14:22:52-04:00
3329043 RED+BLUE STRATEGIES d97d6f2c-29fd-4968-b5e6-8e7eedddf4b7 Q1 RED+BLUE STRATEGIES 400693064 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) 2025 first_quarter PHA H.R. 1968 - Full Year Continuing Resolution - Issues related to funding within the Department of Health and Human Services and its agencies for coverage of prescription medications. S. 891 - The Bipartisan Health Care Act - Policies impacting the treatment of pharmacy benefit managers in prescription medication supply chains. Issues related to pharmacy benefit managers in government and commercial insurance sectors. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2025-04-05T12:56:03-04:00
3329595 REPUBLIC CONSULTING, LLC 90718524-5710-4e4e-9cd2-d7b80d973af7 Q1 REPUBLIC CONSULTING, LLC 401016871 IQVIA 2025 first_quarter PHA monitor health data policy. Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2025-04-07T16:33:02-04:00
3329613 CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER faf151aa-f701-489b-8f7a-1f6d35167bd1 Q1 CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER 312496 CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER 2025 first_quarter PHA 340b Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE   38650 0 0 2025-04-07T16:48:26-04:00
3330003 MANATOS & MANATOS f5fba584-a543-46a5-813a-949353c72440 Q1 MANATOS & MANATOS 23634 VANDA PHARMACEUTICALS INC 2025 first_quarter PHA FDA approval of specific medical drugs HOUSE OF REPRESENTATIVES,SENATE     0 0 2025-04-08T15:20:18-04:00
3330037 MCDERMOTT+ LLC 11b36535-6081-4b10-8ec3-6bf378285343 Q1 MCDERMOTT+ LLC 401103287 ALLIANCE FOR RURAL HOSPITAL ACCESS 2025 first_quarter PHA Amendments to Section 340B of the Public Health Service Act regarding eligibility for rural referral centers and sole community hospitals in thefederal discount drug purchasing program. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2025-04-08T15:54:40-04:00
3330402 TRUSYNERGY 37d9c5f9-a8b4-465e-9ce1-57321780d7b6 Q1 TRUSYNERGY 401107715 BURRELL INTERNATIONAL GROUP LLC (ON BEHALF OF SHIONOGI INC.) 2025 first_quarter PHA Funding for the SNS, BARDA, and IBMSC; promoting safer and more effective treatments in the stockpile; promoting onshoring and domestic manufacturing of medicines and their components; prioritizing investments in more effective treatments to combat AMR; PASTEUR Act; reauthorization of the Pandemic and All Hazards Preparedness Act; funding and incentives for MCM development; AMR issues; development of infectious disease and AMR treatments; FY 26 LHHS appropriations; Rare Pediatric Disease Priority Review Voucher HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2025-04-09T12:49:56-04:00
3330495 PUBLIC CITIZEN 5bef0670-8d38-40ec-b45b-5a06061e61a8 Q1 PUBLIC CITIZEN 32362 PUBLIC CITIZEN 2025 first_quarter PHA anti-obesity medication pricing, HHS secretary nomination, Medicare drug price negotiation, international reference price negotiation price caps, number of drugs negotiated, out of pocket caps, inflation rebates, negotiation delay periods, direct-to-consumer pharmaceutical telehealth; Medicare drug price negotiation; HHS nomination, Deputy HHS Secretary, and CMS nominations, Medicare drug price negotiation, Capping Prescription Costs Act, National Institute for Biomedical Research and Development legislation, Protecting Patients from Deceptive Drug Ads Online Act, H.R. 946 Orphan CURES Act; Medicare drug price negotiation eligibility delay period, S.652 Protecting Patients from Deceptive Drug Ads Online Act, EPIC Act (H.R. 1492 / S. 832), ORPHAN Cures Act (H.R.946), and MINI Act (H.R.1672); Medicare drug price negotiation delay periods and exemptions. HOUSE OF REPRESENTATIVES,SENATE   76570 0 0 2025-04-09T14:04:19-04:00
3331016 KEEFE STRATEGIES LLC (FKA KEEFE SINGISER PARTNERS) baf857bf-ce81-49fc-9acb-d7c54d2afdf7 Q1 KEEFE STRATEGIES LLC (FKA KEEFE SINGISER PARTNERS) 401105192 CVS HEALTH 2025 first_quarter PHA Issues encompassing general education regarding the pharmacy benefit manager/pharmacy industry. Issues related to access and affordability of healthcare, prescription drugs, and generic drugs. HOUSE OF REPRESENTATIVES,SENATE 25000   0 0 2025-04-10T13:19:43-04:00
3331017 FLYNN & ASSOCIATES, INC. c103dfca-1963-4145-9a35-d29d46ea1a23 1T FLYNN & ASSOCIATES, INC. 15020 PHARMACEUTICAL INDUSTRY LABOR-MANAGEMENT ASSOCIATION 2025 first_quarter PHA PBM Price Reforms, HOUSE OF REPRESENTATIVES,SENATE 60000   0 1 2025-04-10T13:22:32-04:00
3331442 DAVE KOLBE CONSULTING 3a2c3049-4b50-4c1d-bfa9-d575e3bb18d4 Q1 DAVE KOLBE CONSULTING 401104329 PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION 2025 first_quarter PHA H.R. 1492 (EPIC Act) - Asking members to co-sponsor HR 1492 which fixes the Inflation Reduction Act's small molecule "pill penalty" to ensure continued R&D investments into small molecule medicines. HOUSE OF REPRESENTATIVES 30000   0 0 2025-04-10T17:14:49-04:00
3331479 NATIONAL GROCERS ASSOCIATION 469f73a8-ff48-4e62-b346-85129a9a19d5 Q1 NATIONAL GROCERS ASSOCIATION 27924 NATIONAL GROCERS ASSOCIATION 2025 first_quarter PHA Pharmacy Direct and Indirect Remuneration Fee Reform Pharmacy Benefit Manager Transparency Pharmacy Quality Measures Standardized pharmacy performance measures Any Willing Pharmacy HOUSE OF REPRESENTATIVES,SENATE   229505 0 0 2025-04-10T17:31:13-04:00
3331499 MASON STREET CONSULTING, LLC 9ec5c1e7-1cb2-4508-991f-5c6dadf7140b Q1 MASON STREET CONSULTING, LLC 401105150 CAPITAL RX INC. 2025 first_quarter PHA PBM Reform. Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2025-04-10T18:13:35-04:00
3331503 MASON STREET CONSULTING, LLC 36d5a403-ed47-4634-ba70-e9f0f4ccd5c8 Q1 MASON STREET CONSULTING, LLC 401105150 DOMPE US INC. 2025 first_quarter PHA Tariffs on orphan drugs. Commerce, Dept of (DOC),Health & Human Services, Dept of (HHS),White House Office 30000   0 0 2025-04-10T18:19:09-04:00
3331558 MR. H.R. BERT PENA 82ae1e25-cff8-46a8-8516-7473a99e43f6 Q1 MR. H.R. BERT PENA 400323519 MARGO RX LLC(DBA RICHARD'S PHARMACY) 2025 first_quarter PHA PBM issues Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES     0 0 2025-04-11T07:42:37-04:00
3332131 TARPLIN, DOWNS & YOUNG, LLC b0afc1d3-c0ae-414e-a209-ddef7a33fd87 Q1 TARPLIN, DOWNS & YOUNG, LLC 304736 HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) 2025 first_quarter PHA General issues related to access to medication assisted treatment Implementation of Public Law 113-54 (DSCSA) Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office 80000   0 0 2025-04-11T15:16:13-04:00
3332172 HOLLAND & KNIGHT LLP f3b8fdec-5485-4ce8-b275-1726fb0a8979 Q1 HOLLAND & KNIGHT LLP 18466 VIATRIS INC 2025 first_quarter PHA Safe Act of 2025; Supply Chain Issues; E-labeling; Inflation Reduction Act Implementation; Improving Generic Drug Access; PEPFAR; Drug Shortages; Medicaid Generics Penalty. Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2025-04-11T16:05:38-04:00
3332307 INDEPENDENT PHARMACY COOPERATIVE 7317b8e6-8a31-4137-b762-db09a46de00a Q1 INDEPENDENT PHARMACY COOPERATIVE 313098 INDEPENDENT PHARMACY COOPERATIVE 2025 first_quarter PHA IPC supports Protecting Pharmacies in Medicaid Act (S.927) IPC supports Patients Before Middlemen Act (S 882). IPC supports Continuing Resolution (H.R. 1968) ECAPS provision CMS Implementation of drug provisions of the IRA 2022-including the drug negotiation provision with changes. Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE   40000 0 0 2025-04-12T11:44:20-04:00
3332634 STUMPTOWN STRATEGIES 30e28f94-08b0-419a-9f6f-d8fa45b6174a Q1 STUMPTOWN STRATEGIES 401106433 PRIME THERAPEUTICS 2025 first_quarter PHA HR 2214 DRUG Act Delinking, PBM Issues HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2025-04-13T13:40:30-04:00
3332650 GOVERNMENT COUNSEL, LLC 38bf3b17-99a4-4cf2-9fba-e00d6884b65f Q1 GOVERNMENT COUNSEL, LLC 401105070 HEALTHCARE DISTRIBUTION ALLIANCE 2025 first_quarter PHA Implementation of Public Law 113-54 (DSCSA). HOUSE OF REPRESENTATIVES 60000   0 0 2025-04-13T13:53:44-04:00
3332898 WAKEFERN FOOD CORP. dbe02749-26f2-4cf3-8772-fe0a6bb24131 Q1 WAKEFERN FOOD CORP. 400588798 WAKEFERN FOOD CORP. 2025 first_quarter PHA Protecting Pharmacies In Medicaid Act (S. 927) Patients Before Middlemen Act (S. 882) Prescription Drug Transparency and Affordability Act (No bill number yet) HOUSE OF REPRESENTATIVES,SENATE     0 0 2025-04-14T09:03:43-04:00
3333389 KOUNTOUPES DENHAM CARR & REID, LLC 97a00079-a2c2-4d80-85de-866a379563e5 Q1 KOUNTOUPES DENHAM CARR & REID, LLC 320918 AMERICAN KRATOM ASSOCIATION 2025 first_quarter PHA Issues related to Food and Drug Administration regulatory and consumer access. Issues related to H.R. 5905, Federal Kratom Consumer Protection Act, and the Fiscal Year 2026 Agriculture Appropriations bills. HOUSE OF REPRESENTATIVES 50000   0 0 2025-04-14T12:17:24-04:00
3333530 KOUNTOUPES DENHAM CARR & REID, LLC eb64a006-01a8-4014-9d4d-89de8be2e62e Q1 KOUNTOUPES DENHAM CARR & REID, LLC 320918 CENCORA INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) 2025 first_quarter PHA Issues related to the pharmaceutical supply chain, drug shortages, and national stockpiles. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2025-04-14T13:54:26-04:00
3333562 KOUNTOUPES DENHAM CARR & REID, LLC 29faf07b-aa29-4154-a82f-27cbcd2cf2d5 Q1 KOUNTOUPES DENHAM CARR & REID, LLC 320918 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 2025 first_quarter PHA General issues related to over-the-counter (OTC) pharmaceutical supply chain. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2025-04-14T14:09:21-04:00
3333596 KOUNTOUPES DENHAM CARR & REID, LLC 0499739e-1b04-4d9a-b2b9-fbc48ac5dd7c Q1 KOUNTOUPES DENHAM CARR & REID, LLC 320918 CVS HEALTH 2025 first_quarter PHA Issues related to pharmaceutical supply chains. HOUSE OF REPRESENTATIVES 60000   0 0 2025-04-14T14:23:49-04:00
3334406 CORNERSTONE GOVERNMENT AFFAIRS, INC. a67dc24f-7edf-4bd4-88cb-f4234bf63075 Q1 CORNERSTONE GOVERNMENT AFFAIRS, INC. 75557 CHILDREN'S NATIONAL MEDICAL CENTER 2025 first_quarter PHA Health-related issues including reimbursement, research, public-health & clinical care. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE 50000   0 0 2025-04-15T09:58:28-04:00
3334574 POLSINELLI PC 50c4ef46-8e7b-4694-bcd9-eff72136bdf8 Q1 POLSINELLI PC 314911 RESQ PHARMA 2025 first_quarter PHA FDA Regulatory Issues HOUSE OF REPRESENTATIVES 10000   0 0 2025-04-15T10:50:49-04:00
3335236 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 8be03bc0-0ca4-4516-967b-4a31157731c9 Q1 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 29403 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 2025 first_quarter PHA - The Wastewater Infrastructure Pollution Prevention and Environmental Safety (WIPPES) Act Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE,White House Office 201227   0 0 2025-04-15T15:06:26-04:00
3335317 THE ROTUNDA GROUP LLC f73e092f-e3d7-4177-9e45-1abb3114d6c6 Q1 THE ROTUNDA GROUP LLC 401104124 HEALTHPLAN DATA SOLUTIONS, INC. 2025 first_quarter PHA pharmacy benefit reform; pharmacy payment integrity HOUSE OF REPRESENTATIVES 10000   0 0 2025-04-15T15:22:10-04:00
3335323 ICE MILLER LLP f478b02c-a775-4da8-adae-795a0841287c Q1 ICE MILLER LLP 67854 COALITION FOR RESPONSIBLE COMPOUDING INC. 2025 first_quarter PHA Educating Congress and the Executive Branch about compounding procedures and standards. HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2025-04-15T15:24:33-04:00
3335794 FORBES-TATE 92be7aba-7d71-4c05-8bfe-5f137167a553 Q1 FORBES-TATE 400976792 PHRMA 2025 first_quarter PHA Issues pertaining to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program. HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2025-04-15T18:48:05-04:00
3335912 FORBES-TATE a89c3bd6-a4cd-4d91-b48e-8aaa972980ab Q1 FORBES-TATE 400976792 INDEPENDENT PHARMACY COOPERATIVE 2025 first_quarter PHA Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2025-04-15T21:14:52-04:00
3335948 BROWNSTEIN HYATT FARBER SCHRECK, LLP e6e83437-9dc5-43d7-8e75-6cce2d72f3f5 Q1 BROWNSTEIN HYATT FARBER SCHRECK, LLP 7257 WALGREEN CO. 2025 first_quarter PHA Issues related to drug pricing reform and transparency Issues related to access and distribution of pharmaceutical products Issues related to Artificial Intelligence in healthcare Issues regarding immunization and vaccines HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2025-04-15T22:25:11-04:00
3335982 PENN AVENUE PARTNERS 1095b415-7af2-4cd9-88bb-43d82d912eba Q1 PENN AVENUE PARTNERS 400918672 ALKERMES, INC. 2025 first_quarter PHA Regulatory and legislative issues impacting Alkermes. Appropriations. HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA) 60000   0 0 2025-04-16T04:40:41-04:00
3336043 PENN AVENUE PARTNERS cca0fa42-12e9-481d-a0d8-2414681981d7 Q1 PENN AVENUE PARTNERS 400918672 UNITEDHEALTH GROUP, INC. 2025 first_quarter PHA Pharmacy benefit related issues. HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA) 90000   0 0 2025-04-16T06:57:23-04:00
3336079 TAUZIN STRATEGIC NETWORKS 01b636fd-2b49-43fd-ad28-3c8c604d8a13 Q1 TAUZIN STRATEGIC NETWORKS 400786367 RAZORMETRICS 2025 first_quarter PHA Lowering Medicare & Medicaid pharmaceutical spend with advanced cost containment systems Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 37500   0 0 2025-04-16T08:18:26-04:00
3336289 BOLD STRATEGIES, LLC b098a7f3-9d02-4b3b-bbba-56793e1dede2 Q1 BOLD STRATEGIES, LLC 401104653 MORRIS & DICKSON CO., LLC 2025 first_quarter PHA Prescription drug issues generally. HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2025-04-16T10:13:05-04:00
3336768 ICE MILLER LLP 8eb6cd59-f4ec-4bf8-847f-85daea035623 1A ICE MILLER LLP 67854 COALITION FOR RESPONSIBLE COMPOUDING INC. 2025 first_quarter PHA Educating Congress and the Executive Branch about compounding procedures and standards. Food & Drug Administration (FDA) 10000   0 0 2025-04-16T12:00:16-04:00
3336858 TRAVERE THERAPEUTICS 1609b792-82d5-4214-b33b-d9df2e0fbc5a Q1 TRAVERE THERAPEUTICS 401104190 TRAVERE THERAPEUTICS 2025 first_quarter PHA HR 946, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act) HOUSE OF REPRESENTATIVES,SENATE   160000 0 0 2025-04-16T12:25:40-04:00
3336930 FAEGRE DRINKER BIDDLE & REATH LLP 9b7d7737-5189-44e9-924b-548750177d97 Q1 FAEGRE DRINKER BIDDLE & REATH LLP 12631 NATIONAL ASSOCIATION OF BOARDS OF PHARMACY 2025 first_quarter PHA Medication safety; pharmacy regulation and licensure; drug supply chain security; prescription drug monitoring programs; and health provider workforce (HR 929 Dr. Lorna Breen Health Care Provider Protection Reauthorization Act). Combatting the opioid epidemic including ensuring MOUD access, DEA telehealth rules, and H.R. 2483 SUPPORT for Patients and Communities Reauthorization Act. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2025-04-16T12:53:05-04:00
3336995 HEALTHSPERIEN c0d2a6bd-3e89-4b84-8c48-8c640d7ff13f Q1 HEALTHSPERIEN 401103150 EXACT CARE PHARMACY 2025 first_quarter PHA Advocate for codifying definition for long-term care pharmacy. (S. 1574), Advocate for inclusion of chronic care pharmacy in CMS and CMMI payment approaches Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE     0 0 2025-04-16T13:07:30-04:00
3337244 RICCHETTI INCORPORATED 16a946c2-a490-46f3-906e-626831af6b1e 1T RICCHETTI INCORPORATED 62778 EISAI, INC. 2025 first_quarter PHA Issues related to coverage of Alzheimer's drugs and diagnostics under Federal health care programs; Issues related to drug pricing and access, and Medicare and Medicaid reimbursement; Issues related to pharmaceutical industry, generally HOUSE OF REPRESENTATIVES,SENATE 30000   0 1 2025-04-16T14:22:33-04:00
3337248 RICCHETTI INCORPORATED b032a4f8-e07a-48ed-b058-abb07e78234c Q1 RICCHETTI INCORPORATED 62778 IPSEN BIOPHARMACEUTICALS, INC. 2025 first_quarter PHA Issues related to pharmaceutical industry, generally; Issues related to development of products to treat limb spasticity and fibrodysplasia ossificans progressiva (FOP) HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2025-04-16T14:23:55-04:00
3337461 ELI LILLY AND COMPANY abca769c-cbf5-4784-8de6-1053bffd86f8 Q1 ELI LILLY AND COMPANY 13392 ELI LILLY AND COMPANY 2025 first_quarter PHA Hospital discounts; 340B program; Prescription drug value, access, quality and compliance with Drug Quality and Safety Act HOUSE OF REPRESENTATIVES,SENATE   3350000 0 0 2025-04-16T15:02:51-04:00
3337472 NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD) 0eda37d8-70df-4eee-8875-6e1f22f28074 Q1 NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD) 28264 NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) 2025 first_quarter PHA Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. Prescription Drug User Fee Act (PDUFA) Reauthorization. User Fee Agreements. RARE Act. Inflation Reduction Act Implementation. PRV Reauthorization. Accelerated Approval. S.705: Innovation in Pediatric Drugs Act of 2025. H.R.1414: Camerons Law. Promising Pathways Act 2.0. Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   50000 0 0 2025-04-16T15:06:21-04:00
3337531 E3 STRATEGIC CONSULTING GROUP 4e26ad16-7cb2-485c-855a-36aa1fa8a8f6 Q1 E3 STRATEGIC CONSULTING GROUP 401104104 PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION 2025 first_quarter PHA Prescription drug industry issues relating to domestic construction and maintenance, prescription drug pricing, supply chain issues, pharmacy benefit managers transparency issues, Intellectual property, and employment issues, generally; S. 1040, Drug Competition Enhancement Act; H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2025-04-16T15:18:21-04:00
3337686 HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) bced6e52-094b-4871-8579-c31eb2503d4f Q1 HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) 28776 HEALTHCARE DISTRIBUTION ALLIANCE (FORMERLY - HDMA) 2025 first_quarter PHA Opioid Abuse - General issues related to access to medication assisted treatment Implementation of Public Law 113-54 (DSCSA) Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE   508963 0 0 2025-04-16T15:52:05-04:00
3337734 THEGROUP DC, LLC 961cacbe-311a-4b8b-acc0-5e2e12409a28 1T THEGROUP DC, LLC 401103834 GILEAD SCIENCES, INC. 2025 first_quarter PHA General advocacy surrounding pharmaceuticals and drug development. HOUSE OF REPRESENTATIVES 60000   0 1 2025-04-16T16:03:16-04:00
3337818 SAREPTA THERAPEUTICS, INC. 434d4074-3afb-46b9-ad6e-c8eab2729ae3 Q1 SAREPTA THERAPEUTICS, INC. 401103510 SAREPTA THERAPEUTICS, INC. 2025 first_quarter PHA Issues related to the Inflation Reduction Acts prescription drug provisions HOUSE OF REPRESENTATIVES,SENATE   320000 0 0 2025-04-16T16:18:06-04:00
3338035 MR. BRIAN KELLY f52ac711-dd2d-4338-aaf0-2964bc3821d5 1A MR. BRIAN KELLY 40024191 TAKEDA PHARMACEUTICAL COMPANY 2025 first_quarter PHA Trade and tariffs Commerce, Dept of (DOC),U.S. Trade Representative (USTR),White House Office 10000   0 0 2025-04-16T16:46:12-04:00
3338431 ASSOCIATION FOR ACCESSIBLE MEDICINES a2932449-d86b-4bf4-8b97-72e156da7087 Q1 ASSOCIATION FOR ACCESSIBLE MEDICINES 16032 ASSOCIATION FOR ACCESSIBLE MEDICINES 2025 first_quarter PHA Prescription Drug Costs. H.R.1843 - To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. S.1302: A bill to provide for increased transparency in generic drug applications. H.R.1396: To amend the Internal Revenue Code of 1986 to establish the generic drugs and biosimilars production credit, and for other purposes. Drug Shortages. Biosimilar Interchangeability. H.R.1051: To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of an abbreviated new drug application submitted by a subsequent applicant in the case of a failure by a first applicant to commence commercial marketing within a certain period, and for other purposes. E-Labeling. Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   650000 0 0 2025-04-16T18:37:15-04:00
3338630 BALLARD PARTNERS c683cca6-ddce-4647-bbc8-6c6fdd480fd1 Q1 BALLARD PARTNERS 401104288 NATIONAL ASSOCIATION OF CHAIN DRUG STORES 2025 first_quarter PHA Lower healthcare costs, pharmacy coverage and reimbursement issues, (does not include any PBM issues). Health & Human Services, Dept of (HHS),White House Office 90000   0 0 2025-04-16T22:00:40-04:00
3338913 FORBES-TATE 819d7189-ab54-4932-a69d-96da7110e473 Q1 FORBES-TATE 400976792 CALIFORNIA LIFE SCIENCES ASSOCIATION 2025 first_quarter PHA Issues related to the life sciences industry; Issues related to drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to Pharmacy Benefit Managers. HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2025-04-17T08:45:21-04:00
3339177 BROYDRICK & ASSOCIATES da9107d7-d633-4432-a07f-227fa84c2ac6 Q1 BROYDRICK & ASSOCIATES 7268 TONIX PHARMACEUTICALS 2025 first_quarter PHA Funding new drug for PTSD and COVID 19, BARDA appropriations. Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2025-04-17T09:49:39-04:00
3339240 THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH a1c36a61-212f-42ef-880b-850b9cc62eb4 Q1 THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH 401104060 THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH 2025 first_quarter PHA Increasing the affordability and accessibility of treatments for Parkinsons disease. HOUSE OF REPRESENTATIVES,SENATE   160000 0 0 2025-04-17T10:00:34-04:00
3339426 AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS 016d8cea-79f7-4558-9aa5-75df9a48ba25 Q1 AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS 3457 AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS 2025 first_quarter PHA Issues related to FDA authority to manage drug shortages, regulation of pharmacy compounding, and implementation of the Drug Quality and Security Act. Issues related to pharmacy benefit manager (PBM) abuses and transparency (generally, no specific legislation). Issues related to 340B program nondiscrimination and contract pharmacy arrangements (generally, no specific legislation). Issues related to manufacturer attempts to undercut the 340B program (generally, no specific legislation). Issues related to pharmacy residency funding, including support for the Rebuild Americas Health Care Schools Act of 2024 (S. 5397/H.R. 10225). Issues related to drug price negotiations and patient out-of-pocket costs (generally, no specific legislation). Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE   220000 0 0 2025-04-17T10:32:28-04:00
3339603 UNIVERSITY OF IOWA 169b3116-4c6a-4588-887c-31bce7cfc076 Q1 UNIVERSITY OF IOWA 49191 UNIVERSITY OF IOWA 2025 first_quarter PHA N/A HOUSE OF REPRESENTATIVES,SENATE   140000 0 0 2025-04-17T10:55:49-04:00
3339803 MEHLMAN CONSULTING, INC. 0479277a-9c18-4f03-adb0-8c4d56737d17 Q1 MEHLMAN CONSULTING, INC. 284950 AARP, INC. 2025 first_quarter PHA Issues related to the cost of prescription drugs. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2025-04-17T11:23:27-04:00
3339854 MEHLMAN CONSULTING, INC. 82aaa504-babd-453b-9df1-5a812fdc9634 Q1 MEHLMAN CONSULTING, INC. 284950 AMERICA'S HEALTH INSURANCE PLANS 2025 first_quarter PHA Prescription drug pricing. HOUSE OF REPRESENTATIVES,SENATE 90000   0 0 2025-04-17T11:26:42-04:00
3339960 MEHLMAN CONSULTING, INC. 53b42279-ea31-400c-9267-16481abb0e8b Q1 MEHLMAN CONSULTING, INC. 284950 ASSOCIATION OF ACCESSIBLE MEDICINES 2025 first_quarter PHA Issues related to pharmaceutical manufacturing supply chain. HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE 60000   0 0 2025-04-17T11:32:58-04:00
3340030 MEHLMAN CONSULTING, INC. d245f276-bcba-45e2-9ea6-211ce212ca15 Q1 MEHLMAN CONSULTING, INC. 284950 BLUE CROSS BLUE SHIELD MICHIGAN 2025 first_quarter PHA Issues related to prescription drug pricing. HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2025-04-17T11:38:23-04:00
3340035 MEHLMAN CONSULTING, INC. 5d54af2f-17e7-4606-b51d-e74e4980f82a Q1 MEHLMAN CONSULTING, INC. 284950 BLUE SHIELD OF CALIFORNIA 2025 first_quarter PHA Issues related to prescription drug pricing and transparency. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2025-04-17T11:39:04-04:00
3340083 MEHLMAN CONSULTING, INC. 01e04265-4c25-42a7-890b-286c000310a7 Q1 MEHLMAN CONSULTING, INC. 284950 THE CAMPAIGN FOR SUSTAINABLE RX PRICING 2025 first_quarter PHA Prescription drug pricing issues. H.R. 1843/S. 1302 - Increasing Transparency in Generic Drug Applications Act. HOUSE OF REPRESENTATIVES,SENATE 90000   0 0 2025-04-17T11:41:28-04:00
3340147 BURRELL INTERNATIONAL GROUP LLC 848e9fc9-57cc-4a92-b58f-d878d406c25b Q1 BURRELL INTERNATIONAL GROUP LLC 401103483 TONIX PHARMACEUTICALS HOLDING CORP. 2025 first_quarter PHA LHHS Appropriation R&D Funding, Pandemic Preparedness Funding for Next Generation Products; FY26 Defense Appropriation for broad-spectrum antivirals, FY26 LHHS for Long COVID and cocaine overdose funding; Alternative to Pain Act and Chronic Pain coverage HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2025-04-17T11:45:34-04:00
3340162 BURRELL INTERNATIONAL GROUP LLC 9b21a77d-a3b3-4a6c-9f35-efb723efc8f0 Q1 BURRELL INTERNATIONAL GROUP LLC 401103483 SHIONOGI INC. 2025 first_quarter PHA FY26 Appropriations and policy for the Strategic National Stockpile, BARDA, and Industrial Base Management Supply Chain, Pandemic and All Hazards Preparedness Act (PAHPA), PASTEUR Act and MCM Development funding; AMR issues. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2025-04-17T11:46:12-04:00
3340182 MEHLMAN CONSULTING, INC. baa6f7ab-d16e-4b91-b68f-ba3cb50b1b4b Q1 MEHLMAN CONSULTING, INC. 284950 ELEVANCE HEALTH, INC. 2025 first_quarter PHA Prescription Drug Pricing. HOUSE OF REPRESENTATIVES,SENATE 90000   0 0 2025-04-17T11:47:42-04:00
3340498 WAKE FOREST BAPTIST MEDICAL CENTER AFFILIATE OF ADVOCATE HEALTH cea4dd17-7277-4599-94cf-fd914509034f Q1 WAKE FOREST BAPTIST MEDICAL CENTER AFFILIATE OF ADVOCATE HEALTH 401107274 WAKE FOREST BAPTIST MEDICAL CENTER AFFILIATE OF ADVOCATE HEALTH 2025 first_quarter PHA Any bills or provisions related to the 340b drug discount program. HOUSE OF REPRESENTATIVES,SENATE   20000 0 0 2025-04-17T12:30:30-04:00
3340529 DA VINCI GROUP 76d6ec72-7ced-4fef-9a53-8e75ef2d286f Q1 DA VINCI GROUP 11548 BOESEN & SNOW, LLC 2025 first_quarter PHA Health Care Issues and pharmaceutical-related issues, generally; No Specific legislation during this period. HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2025-04-17T12:33:58-04:00
3340611 THE HARPLE GROUP, LLC cf3aad43-77f4-485e-b772-fc68e9b6bc07 Q1 THE HARPLE GROUP, LLC 401108916 PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION (PILMA) 2025 first_quarter PHA Prescription drug industry issues relating to domestic construction and maintenance, and prescription drug pricing Pharmacy Benefit Manager Transparency Act of 2023; Prescription Pricing for the People Act of 2023; HELP Copays Act; Delinking Revenue from Unfair Gouging Act (a/k/a The DRUG Act"); Lowering Drug Costs for American Families Act; Protecting Patients Against PBM Abuses Act; The Drug Act; Lower Costs, More Transparency Act. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2025-04-17T12:42:54-04:00
3340766 MEHLMAN CONSULTING, INC. 6e419229-281f-4547-a572-9754c46564df Q1 MEHLMAN CONSULTING, INC. 284950 WEDGEWOOD PHARMACY LLC 2025 first_quarter PHA Issues related to animal drug compounding. Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2025-04-17T12:58:11-04:00
3341209 FOLEY & LARDNER LLP 438f7918-d7b8-4399-9d28-fb2f83a51839 Q1 FOLEY & LARDNER LLP 15042 ENDO USA, INC., A MALLINCKRODT-ENDO COMPANY 2025 first_quarter PHA Issues related to Domestic manufacturing; Issues related to 340B; implementation of the Inflation Reduction Act and the Bipartisan Infrastructure Bill; Issues related to supply chain resilience. HOUSE OF REPRESENTATIVES,SENATE 70000   0 0 2025-04-17T14:14:43-04:00
3341529 FEROX STRATEGIES 70491116-d60a-4107-8af5-b6e9d89a0cce Q1 FEROX STRATEGIES 401104769 ELI LILLY AND COMPANY 2025 first_quarter PHA Issues related to the pharmaceutical industry. Issues related to Treating and Reducing Obesity. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2025-04-17T14:55:11-04:00
3341573 FEROX STRATEGIES 5640a8ab-ff6e-4ab6-9b04-3bcd34d6eeff Q1 FEROX STRATEGIES 401104769 FRESENIUS KABI USA LLC 2025 first_quarter PHA General patent issues related to generic and biosimilar industries. Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2025-04-17T14:58:14-04:00
3341583 UC HEALTH e34e020d-5ca0-44f3-8deb-f5c2f4bcafeb Q1 UC HEALTH 401103195 UC HEALTH 2025 first_quarter PHA 340B HOUSE OF REPRESENTATIVES,SENATE   50000 0 0 2025-04-17T14:59:50-04:00
3341754 FOLEY & LARDNER LLP e4f46357-f93d-447b-994c-876b7d3df3c5 Q1 FOLEY & LARDNER LLP 15042 ASSOCIATION FOR ACCESSIBLE MEDICINES 2025 first_quarter PHA Issues related to manufacturing and pharmaceutical trade. HOUSE OF REPRESENTATIVES,SENATE,White House Office 50000   0 0 2025-04-17T15:14:10-04:00
3341759 FEROX STRATEGIES b31b5076-fad5-417f-a717-10cc1d03cd8d Q1 FEROX STRATEGIES 401104769 VIATRIS INC 2025 first_quarter PHA Policy and oversight related to the generic pharmaceutical industry. Issues related to drug pricing. Issues related to FDA generic drug approval process. General issues related to Agriculture Appropriations. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 70000   0 0 2025-04-17T15:14:47-04:00
3341837 SIMS STRATEGIES, LLC 17fc3af7-87b4-42fc-a35e-8c723da4b0b9 Q1 SIMS STRATEGIES, LLC 401104546 GLAXOSMITHKLINE, INC. 2025 first_quarter PHA Issues related to prescription drugs, vaccines, and Pharmacy Benefit Managers. SENATE 40000   0 0 2025-04-17T15:20:19-04:00
3341853 FOLEY & LARDNER LLP 653e0e10-50f4-4051-b02a-78b812bedb03 Q1 FOLEY & LARDNER LLP 15042 BLINK HEALTH LTD (A BERMUDA LIMITED COMPANY) 2025 first_quarter PHA Market-based solutions to drug pricing and chain pharmacy barriers to generic pharmaceutical price reduction. HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2025-04-17T15:21:20-04:00
3341903 SUSAN B ANTHONY LIST 05a138f8-0a59-4fc6-89c9-120b78ffa5f3 Q1 SUSAN B ANTHONY LIST 400935704 SUSAN B ANTHONY LIST 2025 first_quarter PHA Shield laws; H.R. 685 Support and Value Expectant Moms and Babies Act; Chemical abortion drugs; H.R.679 To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes; Administration Personnel; Presidential Administration Actions HOUSE OF REPRESENTATIVES,SENATE   600000 0 0 2025-04-17T15:24:54-04:00
3341977 HANCE SCARBOROUGH 075918b8-436e-445d-976b-db3c78835d08 Q1 HANCE SCARBOROUGH 17443 ALLIANCE FOR PHARMACY COMPOUNDING 2025 first_quarter PHA Issues Related to the regulation of pharmacy compounding. Issues related to preserving patient access to compounded medications. Fiscal Year 2025 Appropriations. HR167, the Patient Access to Urgent Use Compounded Medication Act HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2025-04-17T15:30:19-04:00
3342183 MASSACHUSETTS MEDICAL SOCIETY eab10a25-427e-4845-88a2-e4a198249c98 Q1 MASSACHUSETTS MEDICAL SOCIETY 23975 MASSACHUSETTS MEDICAL SOCIETY 2025 first_quarter PHA Prescription Drug Pricing Issues related to prescription drug pricing - no specific bill S. 470/HR 977, The Patient Access to Higher Quality Health Care Act HOUSE OF REPRESENTATIVES,SENATE   80000 0 0 2025-04-17T15:43:22-04:00
3342310 THORN RUN PARTNERS 6a9f7ab0-d270-4266-9e42-19ff783363ab Q1 THORN RUN PARTNERS 400534596 OTSUKA AMERICA PHARMACEUTICAL, INC. 2025 first_quarter PHA Pharmaceutical reimbursement issues. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2025-04-17T15:55:56-04:00
3342371 THORN RUN PARTNERS 5fc241fd-6067-40d0-96ba-eb596c1bed24 1T THORN RUN PARTNERS 400534596 PROFESSIONAL COMPOUNDING CENTERS OF AMERICA 2025 first_quarter PHA Issues related to the Drug Quality and Security Act, Compounding Pharmacy, Reimbursement, and Patient Access, animal compounding, and H.R.167 - Patient Access to Urgent-Use Pharmacy Compounding Act of 2023. H.R.3810 - Drug Origin Transparency Act of 2023. HOUSE OF REPRESENTATIVES,SENATE 30000   0 1 2025-04-17T16:01:28-04:00
3342657 FOLEY & LARDNER LLP 2dedc5f5-85b1-4bf8-bdba-7b904bc44169 Q1 FOLEY & LARDNER LLP 15042 FOUNDATION CONSUMER HEALTHCARE LLC 2025 first_quarter PHA Regulations affecting non-prescription drugs HOUSE OF REPRESENTATIVES,SENATE,White House Office 120000   0 0 2025-04-17T16:39:37-04:00
3342670 WINNING STRATEGIES WASHINGTON 1cc6e8a8-18a1-4137-ae41-1da4ff12c591 Q1 WINNING STRATEGIES WASHINGTON 50796 KALEO 2025 first_quarter PHA Pharmaceutical drug development, including epinephrine for anaphylaxis; drug access and affordability issues HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2025-04-17T16:41:46-04:00
3342815 SQUIRE PATTON BOGGS 2d4ce428-d748-44df-a47c-e82b94a8cb90 Q1 SQUIRE PATTON BOGGS 30906 SK AMERICAS, INC. 2025 first_quarter PHA US pharmaceutical policies. HOUSE OF REPRESENTATIVES,SENATE 220000   0 0 2025-04-17T16:57:49-04:00
3343262 KAISER FOUNDATION HEALTH PLAN INC. f3f05e62-fe86-427d-b966-217856860a3c Q1 KAISER FOUNDATION HEALTH PLAN INC. 21027 KAISER FOUNDATION HEALTH PLAN INC 2025 first_quarter PHA Legislation and regulation regarding pharmaceutical pricing, coverage and care; retail and inpatient pharmacy operations and the role of pharmacy benefit managers. HOUSE OF REPRESENTATIVES,SENATE   3000000 0 0 2025-04-17T19:27:52-04:00
3343426 BALLARD PARTNERS d3c8a27a-243a-48c5-876e-e99ec937d35e Q1 BALLARD PARTNERS 401104288 THE CRANEWARE GROUP (F.K.A. SENTRY DATA SYSTEMS) 2025 first_quarter PHA 340B Drug Discount Program. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office 50000   0 0 2025-04-17T22:20:40-04:00
3343518 HARMONY BIOSCIENCES 5af98c96-7518-4222-bf7f-7d46696c0b2d Q1 HARMONY BIOSCIENCES 401105020 HARMONY BIOSCIENCES 2025 first_quarter PHA H.R. 5547, Maintaining Investments in New Innovation (MINI) Act (118th Congress) H.R. 1492, Ensuring Pathways to Innovative Cures (EPIC) Act (118th Congress) H.R. 6094, Providing Realistic Opportunity To Equal and Comparable Treatment for (PROTECT) Rare Act (118th Congress) H.R. 6664, Innovation in Pediatric Drugs Act (118th Congress) H.R. 7384, Creating Hope Reauthorization Act (118th Congress) H.R. 7383, Retaining Access and Restoring Exclusivity (RARE) Act (118th Congress) H.R.7024, Tax Relief for American Families and Workers Act of 2024 (118th Congress) H.R.3433 / S.2897, Give Kids a Chance Act (118th Congress) HOUSE OF REPRESENTATIVES,SENATE   150000 0 0 2025-04-17T23:19:32-04:00
3343703 VAN SCOYOC ASSOCIATES 818072a9-65a3-468e-95c7-cca4878815dc Q1 VAN SCOYOC ASSOCIATES 39837 ZEBRA TECHNOLOGIES CORP. 2025 first_quarter PHA Temperature monitoring technology issues, as follows: Public Law 118-159, Servicemember Quality of Life Improvement and National Defense Authorization Act for Fiscal Year 2025 H.R.9029/S.4942, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2025 Monitor National Defense Authorization Act for Fiscal Year 2026 Monitor Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2026 HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2025-04-18T07:19:17-04:00
3343830 AARP 3df0c399-ae01-430e-b0f7-eb302f64c329 Q1 AARP 1694 AARP 2025 first_quarter PHA H. Con. Res. 14/S. Con. Res. 7, the Budget Reconciliation Resolution S. 1096, the Preserving Access to Affordable Generics and Biosimilars Act. S. 1095, the Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act. S. 1040, the Drug Competition Enhancement Act. H.R. 9070/S. 1041, the Affordable Prescriptions for Patients Act. S. 1097, the Interagency Patent Coordination and Improvement Act of 2025. No bill number. Discussed pharmacy benefit managers. S. 527, Prescription Pricing for the People Act of 2025. S. 526, the Pharmacy Benefit Manager (PBM) Transparency Act of 2025. S. 229, the Drug-Price Transparency for Consumers (DTC) Act of 2025. No bill number. Discussed Medicare Part D. No bill number. Discussed cap on out-of-pocket prescription drug costs. No bill number. Discussed the Medicare Prescription Payment Plan. No bill number. Discussed the Medicare drug price negotiation program. Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office   6630000 0 0 2025-04-18T08:49:09-04:00
3344058 VENABLE LLP 0ba9298b-66eb-47b2-b94d-75dfc1dddda4 Q1 VENABLE LLP 39941 MEDISCA INC. 2025 first_quarter PHA FDA policy; matters related to pharmacy compounding   60000   0 0 2025-04-18T09:31:27-04:00
3344200 PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION 5b441c67-a7fd-4c9e-beaf-49cf99e827dc Q1 PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION 401103605 PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION 2025 first_quarter PHA Discussed issues related to drug shortages, pandemic preparedness, advanced manufacturing, onshoring/friendshoring initiatives, and robustness of biopharmaceutical supply chains HOUSE OF REPRESENTATIVES,SENATE   50000 0 0 2025-04-18T09:55:14-04:00
3344204 VAN SCOYOC ASSOCIATES 3d909f63-edbd-4398-bd96-af1c7f463104 Q1 VAN SCOYOC ASSOCIATES 39837 NATIONAL ASSOCIATION OF CHAIN DRUG STORES 2025 first_quarter PHA Equitable Community Access to Pharmacist Services Act, Entirety S.891, Bipartisan Health Care Act, PBM reform related issues H.R.2484, Seniors' Access to Critical Medications Act of 2025, Entirety PBM Reform related issues HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2025-04-18T09:56:48-04:00
3344263 HIGHMARK, INC. 7e64aca8-3886-49c3-804f-9da8fd063a9d Q1 HIGHMARK, INC. 18238 HIGHMARK INC 2025 first_quarter PHA Drug Pricing, PBM Reform HOUSE OF REPRESENTATIVES,SENATE   220000 0 0 2025-04-18T10:05:42-04:00

Next page

Advanced export

JSON shape: default, array, newline-delimited, object

CSV options:

CREATE TABLE lobbying_activities (
            id INTEGER PRIMARY KEY,
            filing_uuid TEXT NOT NULL,
            filing_type TEXT NOT NULL,
            registrant_name TEXT NOT NULL,
            registrant_id INTEGER,
            client_name TEXT NOT NULL,
            filing_year INTEGER NOT NULL,
            filing_period TEXT NOT NULL,
            issue_code TEXT,
            specific_issues TEXT,
            government_entities TEXT,
            income_amount INTEGER,
            expense_amount INTEGER,
            is_no_activity INTEGER DEFAULT 0,
            is_termination INTEGER DEFAULT 0,
            received_date TEXT,
            CONSTRAINT fk_activity_filing FOREIGN KEY (filing_uuid)
                REFERENCES lobbying_filings_raw(filing_uuid)
        );
CREATE INDEX idx_act_client_name ON lobbying_activities(client_name COLLATE NOCASE);
CREATE INDEX idx_act_issue_code ON lobbying_activities(issue_code);
CREATE INDEX idx_act_filing_year ON lobbying_activities(filing_year);
CREATE INDEX idx_act_filing_uuid ON lobbying_activities(filing_uuid);
Powered by Datasette · Queries took 5269.094ms · Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API